We are live on
!
Find out more
SEC
Seven Eight Capital Portfolio holdings
AUM
$1.11B
1-Year Est. Return
29.48%
This Fund
S&P 500
This Quarter
Est. Return
+14.58%
1 Year Est. Return
+29.48%
3 Year Est. Return
+13.61%
5 Year Est. Return
+117.69%
10 Year Est. Return
+239.1%
AUM
$865M
AUM Growth
+$9.54M
(+1.1%)
Cap. Flow
-$78.4M
Cap. Flow
% of AUM
-9.07%
Top 10 Holdings %
Top 10 Hldgs %
8.56%
Holding
892
New
315
Increased
150
Reduced
128
Closed
299
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
XP
XP
|
+$7.27M |
| 2 |
Constellation Brands
STZ
|
+$7.01M |
| 3 |
Eli Lilly
LLY
|
+$6.9M |
| 4 |
Automatic Data Processing
ADP
|
+$6.79M |
| 5 |
Nu Holdings
NU
|
+$6.73M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Merck
MRK
|
+$11.9M |
| 2 |
Vertex Pharmaceuticals
VRTX
|
+$11.9M |
| 3 |
Microsoft
MSFT
|
+$11.8M |
| 4 |
Alphabet (Google) Class C
GOOG
|
+$11.7M |
| 5 |
Las Vegas Sands
LVS
|
+$11.2M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 19.67% |
| 2 | Healthcare | 18.49% |
| 3 | Consumer Discretionary | 15.79% |
| 4 | Industrials | 10.31% |
| 5 | Financials | 10.3% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
176
ICU Medical
ICUI
$4.21B
| $1.51M | 0.17% |
+15,092
| New | +$1.48M |
|
177
Ambarella
AMBA
$3.77B
| $1.49M | 0.17% |
24,392
-15,007
| -38% | -$819K |
|
178
Revvity
RVTY
$12.6B
| $1.49M | 0.17% |
+13,626
| New | +$1.31M |
|
179
Telephone and Data Systems
TDS
$3.82B
| $1.49M | 0.17% |
81,085
-26,169
| -24% | -$483K |
|
180
AstraZeneca
AZN
$263B
| $1.48M | 0.17% |
11,024
+3,227
| +41% | +$420K |
|
181
Forward Air
FWRD
$444M
| $1.48M | 0.17% |
23,606
-16,966
| -42% | -$1.14M |
|
182
Omnicell
OMCL
$1.61B
| $1.48M | 0.17% |
+39,413
| New | +$1.45M |
|
183
Editas Medicine
EDIT
$396M
| $1.48M | 0.17% |
+146,345
| New | +$1.28M |
|
|
AZEK
184
DELISTED
The AZEK Co
AZEK
| $1.47M | 0.17% |
+38,494
| New | +$1.2M |
|
185
Starbucks
SBUX
$120B
| $1.46M | 0.17% |
15,208
-77,453
| -84% | -$7.54M |
|
|
AKRO
186
DELISTED
Akero Therapeutics
AKRO
| $1.46M | 0.17% |
+62,464
| New | +$1.23M |
|
187
Shift4
FOUR
$4.2B
| $1.44M | 0.17% |
+19,348
| New | +$1.15M |
|
188
State Street
STT
$50.6B
| $1.42M | 0.16% |
18,287
-69,646
| -79% | -$4.86M |
|
189
Twist Bioscience
TWST
$5.7B
| $1.42M | 0.16% |
38,420
+23,305
| +154% | +$539K |
|
190
Monolithic Power Systems
MPWR
$70.1B
| $1.41M | 0.16% |
2,235
+1,382
| +162% | +$722K |
|
191
Blackrock
BLK
$169B
| $1.41M | 0.16% |
+1,735
| New | +$1.21M |
|
192
Trupanion
TRUP
$1.07B
| $1.4M | 0.16% |
+45,863
| New | +$1.22M |
|
193
BWX Technologies
BWXT
$15.5B
| $1.39M | 0.16% |
+18,110
| New | +$1.39M |
|
194
Acushnet Holdings
GOLF
$5.93B
| $1.36M | 0.16% |
+21,576
| New | +$1.21M |
|
195
Levi Strauss
LEVI
$9.44B
| $1.36M | 0.16% |
+82,277
| New | +$1.22M |
|
196
Atmos Energy
ATO
$28.8B
| $1.35M | 0.16% |
+11,628
| New | +$1.3M |
|
197
Bankunited
BKU
$3.37B
| $1.33M | 0.15% |
+41,051
| New | +$1.06M |
|
198
Edwards Lifesciences
EW
$49.6B
| $1.31M | 0.15% |
17,172
-159,956
| -90% | -$11.1M |
|
199
Ametek
AME
$55.4B
| $1.31M | 0.15% |
7,925
+4,217
| +114% | +$643K |
|
200
Rollins
ROL
$18.3B
| $1.3M | 0.15% |
29,733
-12,078
| -29% | -$470K |
|
Similar funds
PP
ECM
GCAC
CAM
D
GFS
FTIS
AIA
Seven Eight Capital's Q4 2023 Portfolio in Review
As of Q4 2023, Seven Eight Capital held 892 positions worth $865M, up 1.1% from $855M the previous quarter. Its ten largest holdings account for 8.6% of the portfolio.
Seven Eight Capital withdrew a net $78.4M in Q4 2023, closing 299 positions and reducing 128 holdings. Its most notable exit was Merck, an estimated $11.9M position sold in full.
By sector, the portfolio is most concentrated in Technology at 20% of assets, down from 20% a quarter earlier, followed by Healthcare and Consumer Discretionary.
Against the trend, Seven Eight Capital opened a new position in XP worth $8.3M.
- Seven Eight Capital's largest Q4 2023 buy was XP: 318,542 shares worth $8.3M.
- Seven Eight Capital added most to Constellation Brands in Q4 2023, an estimated $7.01M increase.
- Seven Eight Capital's biggest Q4 2023 reduction was Vertex Pharmaceuticals, cutting an estimated $11.9M.
- Seven Eight Capital fully exited Merck in Q4 2023, selling an estimated $11.9M.
- Seven Eight Capital's ten largest holdings make up 8.6% of its $865M portfolio in Q4 2023.
- Seven Eight Capital opened 315 new positions and closed 299 in Q4 2023.
- Seven Eight Capital's portfolio value rose 1.1% quarter-over-quarter to $865M.
Based on Seven Eight Capital's 13F filing for Q4 2023, filed 13 Feb 2024.